URL has been copied successfully!
CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.
The company posted quarterly losses of 71 cents per share which missed the analyst consensus estimate of 57 cents per share. The company reported quarterly sales of $1.083 million which beat the analyst consensus estimate of $493.182 thousand.
“We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026. We are pleased to provide this additional guidance on expected BLA completion following focused filing discussions with FDA. Manufacturing inspection …
Please follow us:
This post was originally published here
